Dr. Plimack On Strategies For Developing Cure For Locally Advanced Urothelial Carcinoma

Dr. Plimack on Strategies for Developing Cure for Locally Advanced Urothelial Carcinoma

Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma

Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer

Dr. Plimack on Immunotherapy Combinations in Bladder Cancer

Expert comment: The JAVELIN Bladder 100 study | Elizabeth Plimack

Medicine Matters oncology

Elizabeth Plimack, MD, on treating 2nd line RCC patients that have received an I-0 combination

Advanced/Metastatic Urothelial Carcinoma: Understanding Novel Immunotherapy Maintenance Strategies

PeerView Oncology

New emerging treatment options and targeted therapies for bladder cancer

Dr. Plimack on the Growth of Immunotherapy in Bladder Cancer

Areas of unmet need for patients with advanced UC

Dr. Plimack on KEYNOTE-045 Trial for Pembrolizumab in Urothelial Carcinoma

Dr. Elizabeth Plimack on Immunotherapy Potential in Bladder Cancer

Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer

Advanced/Metastatic Urothelial Carcinoma: Understanding Novel Immunotherapy Maintenance Strategies

PeerView Oncology

Dr. Elizabeth Plimack on a Hypomethylating Agent Plus Anti-PD-L1 for mUC After Disease Progression

GU Oncology Now

Dr. Plimack on a Phase Ib Study of Pembrolizumab in Bladder Cancer

Targeted Oncology

Why Combination Therapy may be Best for my Kidney Cancer Elizabeth Plimack, MD, MS 10/11/19

Judy Nicholson Kidney Cancer Foundation

Dr. Plimack on Whether Hypomethylating Agents Induce Immune Activation in aUC Resistant to ICI

GU Oncology Now

Elizabeth Plimack, MD, explains identifying good candidates for I-O in bladder cancer

Strategies to improve the outcome in locally advanced pancreatic cancer